Download Integra Connect’s Presentation from ASCO 2022
Integra Connect shared study results underscoring the importance of early and rapid genetic testing for improved survival rates in patients with newly- diagnosed stage-4, non-small cell lung cancer.
Importantly, extrapolating these real-world data findings, the study's researchers concluded that universal molecular testing in this patient population is a critical first step in determining the best course of treatment for patients and thereby improving outcomes, including survival rates.
Interested in learning more about the findings from Integra Connect Databases?
Integra Connect's view the study findings as an opportunity to further educate clinicians about the importance of genetic testing prior to starting patients on a course of therapy, which may include targeted therapies such as immunotherapy and tyrosine kinase inhibitors.
Click here to read more about the study.